All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Trilaciclib Before Gemcitabine/Carboplatin Misses OS End Point in Metastatic TNBC

June 24th 2024

Trilaciclib plus chemotherapy failed to improve overall survival in metastatic triple-negative breast cancer.

ADCs and TKIs Look to Carve Out Their Place in the HER2-Mutant NSCLC Treatment Paradigm

June 24th 2024

A panel of expert clinicians discuss the treatment landscape of HER2-mutant non–small cell lung cancer, highlighting the current roles of ADCs and TKIs, and unmet needs that remain in the space.

Clinical Trial End Points and Genomic Profiling Represent Key Sectors of the Evolving NSCLC Landscape

June 24th 2024

Sid Devarakonda, MD, details the role of surgery for patients with non–small cell lung cancer and approaches for treating patients with metastatic disease.

Fruquintinib Wins European Approval for Pretreated mCRC

June 24th 2024

The European Commission has approved fruquintinib for select patients with pretreated metastatic colorectal cancer.

Patient Selection Takes Priority as Standard of Cares Shift in HR+ and HER2+ Breast Cancer

June 23rd 2024

Lauren E. Nye, MD, discusses the use of CDK4/6 inhibitors in HR-positive metastatic breast cancer and the evolution of ADCs in HER2-positive disease.

Lucio N. Gordan, MD, Discusses Findings of Phase 3 Clinical Trial Supporting Advanced Treatments for Multiple Myeloma in National Broadcast

June 22nd 2024

Lucio Gordan, MD, will join a panel to discuss treatment options for newly-diagnosed, transplant ineligible multiple myeloma.

Garon Discusses the Standing and Future of ADCs, Targeted Therapies in NSCLC

June 22nd 2024

Edward B. Garon, MD, MS, takes stock of the non–small cell lung cancer field in light of recent updates from clinical trials.

Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer

June 21st 2024

First-line lenvatinib plus pembrolizumab demonstrated antitumor activity across various histologic subtypes in advanced or recurrent endometrial cancer.

Frontline Durvalumab/Chemo, Then Maintenance Durvalumab ± Olaparib, Improves ORR in Endometrial Cancer

June 21st 2024

Durvalumab plus chemotherapy, followed by durvalumab maintenance with or without olaparib, improved responses in advanced endometrial cancer.

FDA Approves Adagrasib Plus Cetuximab for KRAS G12C–Mutant CRC

June 21st 2024

The FDA has approved adagrasib plus cetuximab for patients with KRAS G12C–mutant locally advanced or metastatic colorectal cancer.

Tucatinib-Based Regimen Improves Target Deficits, QOL in HER2+ Breast Cancer With Leptomeningeal Metastasis

June 21st 2024

Patients with leptomeningeal metastasis from HER2-positive breast cancer experienced clinical benefit with tucatinib plus trastuzumab and capecitabine.

MB-106 Shows Early Promise in BTKi-Refractory Waldenström Macroglobulinemia/LPL

June 21st 2024

MB-106 showcased a favorable safety profile and elicited responses in heavily pretreated patients with refractory Waldenström macroglobulinemia.

EMA Validates Filings for Subcutaneous Formulation of Nivolumab in Solid Tumors

June 21st 2024

The EMA has validated an extension application for the subcutaneous formulation of nivolumab in adult patients with solid tumor indications.

Mirvetuximab Soravtansine Elicits Benefits in Ovarian Cancer Regardless of Dose Modifications

June 21st 2024

Mirvetuximab soravtansine generated PFS, OS, and ORR improvements in patients with ovarian cancer who required dose modifications in the MIRASOL trial.

Researchers Honored for Outstanding Contributions to Cancer Care

June 21st 2024

Three Huntsman Cancer Institute researchers have recently been recognized for their work as outstanding faculty members at the University of Utah.

Jhaveri Discusses the First-in-Human Study of RLY-2608 in Advanced Solid Tumors

June 21st 2024

Komal Jhaveri, MD, FACP, highlights the novel PI3Kα inhibitor RLY-2608 and discusses the details of the first-in-human trial of the agent.

Durvalumab Combo Before Olaparib-Based Maintenance Sustains PFS Benefit in BRCA-Unmutated Ovarian Cancer

June 20th 2024

Durvalumab/chemotherapy/bevacizumab, then durvalumab/bevacizumab/olaparib maintenance, sustained a PFS benefit in BRCA-unmutated advanced ovarian cancer.

ROCSAN Study Step I Misses 16-Week ORR End Point in Endometrial or Ovarian Carcinosarcoma

June 20th 2024

ROCSAN step 1 did not meet its primary end point of 16-week response rate with niraparib or dostarlimab/niraparib in endometrial/ovarian carcinosarcoma.

Vibostolimab Plus Pembrolizumab Fails to Boost Efficacy in Pretreated PD-L1+ Cervical Cancer

June 20th 2024

Vibostolimab plus pembrolizumab was not superior to pembrolizumab monotherapy in pretreated PD-L1–positive advanced cervical cancer.

Addition of XB2001 to Chemo Improves Safety in Advanced Pancreatic Cancer

June 20th 2024

XB2001 plus chemotherapy improved safety and was tied to a trend toward improved overall survival in pretreated advanced pancreatic cancer.